Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges
{{output}}
Sunvozertinib has emerged as one of the most promising tyrosine kinase inhibitors (TKIs) for previously treated non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations, a molecular subset wit... ...
